Transcatheter hepatic artery chemoembolization(TACE)is a universal treatment for patients with hepatocellular carcinoma(HCC)that inhibits tumor growth by cutting off the blood supply and provides chemotherapeutics loc...Transcatheter hepatic artery chemoembolization(TACE)is a universal treatment for patients with hepatocellular carcinoma(HCC)that inhibits tumor growth by cutting off the blood supply and provides chemotherapeutics locally to the tumor.The strategy of combining TACE formulation with image-guided ablation holds tremendous potential,but patient tolerance and undesired toxicity/immunosuppression remains a challenge.The application of nanotechnology in TACE opens new doors for the treatment of HCC.Strikingly,nanomaterials or nano-drugs dispersed in the TACE formulation can effectively improve the delivery efficiency of drugs by achieving both controlled and continuous release.In addition,the utilization of multifunctional nanoparticles can provide guidance and monitoring for various advanced imaging methods for TACE treatment,and can realize the combination therapy of thermal ablation,microwave ablation,in situ radiotherapy,and other therapies,greatly expanding the therapeutic strategies available for HCC treatment.Here,the current exploration of nanotechnology in TACE of HCC is briefly summarized and the challenges of TACE with nanoformulations for clinical translation are comprehensively discussed.展开更多
Interventional embolization is one of the most common treatment strategies in the clinical cancer treatment,especially in liver cancer(Sieghart et al.,2015).However,unstable dispersion and rapid drug release are the b...Interventional embolization is one of the most common treatment strategies in the clinical cancer treatment,especially in liver cancer(Sieghart et al.,2015).However,unstable dispersion and rapid drug release are the bottlenecks in clinical practice.The superstable homogeneous iodinated formulation technology(SHIFT)in interventional embolization treatment has achieved homogeneous dispersion of drugs in lipiodol embolic agent,showing promising clinical translation prospects(Chen et al.,2020 a;He et al.,2022 a.展开更多
Minimally invasive interventional embolization has tremendous advantages over conventional surgery in the treatment of vascular diseases and malignant tumors.Particularly,liquid embolic agents have garnered much atten...Minimally invasive interventional embolization has tremendous advantages over conventional surgery in the treatment of vascular diseases and malignant tumors.Particularly,liquid embolic agents have garnered much attention owing to their properties of deep vascular penetration and full occlusion of vasculature independent of thrombus formation,which relies on the patient’s coagulation system.Despite their drawbacks,traditional liquid embolic agents,such as lipiodol,N-butyl-2-cyanoacrylate,and Onyx,have benefited numerous patients.The original liquid embolic agents have been modified and optimized,and novel liquid embolic agents have also been developed using different strategies and mechanisms.This minireview provides a brief overview of liquid embolic agents,including approved and potential ones.Challenges,prospects,and rational design guidelines are also discussed.This review may spark interest in liquid embolic agents and open new avenues for the smart design of improved embolic agents in the development of personalized and precision medicine.展开更多
基金supported by the Major State Basic Research Development Program of China(No.2017YFA0205201)the National Natural Science Foundation of China(Nos.81925019,81422023 and U1705281)+1 种基金the Fundamental Research Funds for the Central Universities(Nos.20720190088 and 20720200019)the Program for New Century Excellent Talents in University,China(No.NCET-13-0502)。
文摘Transcatheter hepatic artery chemoembolization(TACE)is a universal treatment for patients with hepatocellular carcinoma(HCC)that inhibits tumor growth by cutting off the blood supply and provides chemotherapeutics locally to the tumor.The strategy of combining TACE formulation with image-guided ablation holds tremendous potential,but patient tolerance and undesired toxicity/immunosuppression remains a challenge.The application of nanotechnology in TACE opens new doors for the treatment of HCC.Strikingly,nanomaterials or nano-drugs dispersed in the TACE formulation can effectively improve the delivery efficiency of drugs by achieving both controlled and continuous release.In addition,the utilization of multifunctional nanoparticles can provide guidance and monitoring for various advanced imaging methods for TACE treatment,and can realize the combination therapy of thermal ablation,microwave ablation,in situ radiotherapy,and other therapies,greatly expanding the therapeutic strategies available for HCC treatment.Here,the current exploration of nanotechnology in TACE of HCC is briefly summarized and the challenges of TACE with nanoformulations for clinical translation are comprehensively discussed.
基金supported by the Major State Basic Research Development Program of China(2017YFA0205201)the National Natural Science Foundation of China(81925019,U1705281)。
文摘Interventional embolization is one of the most common treatment strategies in the clinical cancer treatment,especially in liver cancer(Sieghart et al.,2015).However,unstable dispersion and rapid drug release are the bottlenecks in clinical practice.The superstable homogeneous iodinated formulation technology(SHIFT)in interventional embolization treatment has achieved homogeneous dispersion of drugs in lipiodol embolic agent,showing promising clinical translation prospects(Chen et al.,2020 a;He et al.,2022 a.
基金Y.J.,Y.Z.,and Z.L.contributed equally to this work.This work was supported by the Major State Basic Research Development Program of China[2017YFA0205201]the National Natural Science Foundation of China(NSFC)[81925019 and U1705281]+1 种基金the Fundamental Research Funds for the Central Universities[20720190088 and 20720200019]and the Program for New Century Excellent Talents in University,China[NCET-13-0502].
文摘Minimally invasive interventional embolization has tremendous advantages over conventional surgery in the treatment of vascular diseases and malignant tumors.Particularly,liquid embolic agents have garnered much attention owing to their properties of deep vascular penetration and full occlusion of vasculature independent of thrombus formation,which relies on the patient’s coagulation system.Despite their drawbacks,traditional liquid embolic agents,such as lipiodol,N-butyl-2-cyanoacrylate,and Onyx,have benefited numerous patients.The original liquid embolic agents have been modified and optimized,and novel liquid embolic agents have also been developed using different strategies and mechanisms.This minireview provides a brief overview of liquid embolic agents,including approved and potential ones.Challenges,prospects,and rational design guidelines are also discussed.This review may spark interest in liquid embolic agents and open new avenues for the smart design of improved embolic agents in the development of personalized and precision medicine.
